Intellia Therapeutics NTLA
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 78th percentile, 5-year average -6.9x
Below its usual level · 33rd percentile, 5-year average 2.9x
#3275 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 20th percentile, 5-year average 65.6x
#4776 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.22 | – | 2.92 | 33% (cheaper than usual) | #3275 of 5330 (1 = cheapest) |
| PE | -2.90 | -3.03 | -6.90 | 78% (pricier than usual) | – |
| PS | 25.74 | 20.68 | 65.59 | 20% (cheaper than usual) | #4776 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NTLA.
Sign in to join the discussion.